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ABSTRACT
The development of a new male contraceptive requires a
transition from animal model to human and an understanding of
the mechanisms involved in the target’s inhibition of human
spermatozoan fertility. We now report that semenogelin
(SEMG1) and anti-EPPIN antibodies to a defined target site of
21 amino acids on the C terminal of EPPIN cause the loss of
intracellular calcium, as measured by Fluo-4. The loss of
intracellular calcium explains our previous observations of an
initial loss of progressive motility and eventually the complete
loss of motility when spermatozoa are treated with SEMG1 or
anti-EPPIN antibodies. Thimerosal can rescue the effects of
SEMG1 on motility, implying that internal stores of calcium are
not depleted. Additionally, SEMG1 treatment of spermatozoa
decreases the intracellular pH, and motility can be rescued by
ammonium chloride. The results of this study demonstrate that
EPPIN controls sperm motility in the ejaculate by binding
SEMG1, resulting in the loss of calcium, most likely through a
disturbance of internal pH and an inhibition of uptake
mechanisms. However, the exact steps through which the
EPPIN-SEMG1 complex exerts its effect on internal calcium
levels are unknown. Anti-EPPIN antibodies can substitute for
SEMG1, and, therefore, small-molecular weight compounds that
mimic anti-EPPIN binding should be able to substitute for
SEMG1, providing the basis for a nonantibody, nonhormonal
male contraceptive.
calcium, contraception, EPPIN, male contraception, semen,
semenogelin, sperm, sperm motility and transport, spermatozoa
INTRODUCTION
A new male contraceptive will require a transition from
animal model to human and an understanding of the
mechanisms involved in the target’s inhibition of human
spermatozoan fertility. In 2004, O’Rand et al. [1] reported that
male monkeys immunized with the male-specific protein
EPPIN (official symbol, SPINLW1) could develop high titers
of anti-EPPIN antibodies and become reversibly infertile.
Subsequent work characterized EPPIN as a receptor for the
seminal plasma protein semenogelin (SEMG1) [2, 3] and
detailed the inhibition of human sperm motility by anti-EPPIN
antibodies [4]. Anti-EPPIN antibodies, when bound to the
sperm surface, mimic SEMG1 binding, effectively inhibiting
progressive sperm motility and rendering the spermatozoa
infertile [5]. To make the transition from the immunization of
male monkeys to an effective human male contraceptive in
which immunization is not required, we have sought to define
the mechanism through which anti-EPPIN antibodies and
SEMG1 inhibit sperm motility. Consequently, EPPIN’s ability
to inhibit motility when bound by antibody or SEMG1 is of
interest for contraceptive development and for a better
understanding of sperm physiology.
EPPIN coats the surface of human testicular and epididymal
spermatozoa as part of a protein complex containing
lactotransferrin and clusterin [3, 6]. During ejaculation,
SEMG1 binds to EPPIN in the complex [3, 5], inhibiting the
progressive motility of ejaculate spermatozoa. Subsequently,
SEMG1 is hydrolyzed by the serine protease prostate specific
antigen (PSA) [7], and EPPIN modulates PSA hydrolysis of
SEMG1 on the sperm surface [3], resulting in forwardly motile
spermatozoa. Treatment of motile spermatozoa with recombi-
nant SEMG1 fragments containing cysteine residue 239
inhibits forward motility, which can be reversed with PSA
treatment [8]. EPPIN’s function is to bind SEMG1, modulate
PSA activity on the sperm surface, and provide antimicrobial
protection [5, 9]. In this study, we have demonstrated that one
mechanism through which EPPIN is able to bind either
SEMG1 or anti-EPPIN antibody and inhibit motility is the loss
of intracellular calcium.
MATERIALS AND METHODS
Reagents and chemicals were molecular biology grade, purchased from
Sigma (St. Louis, MO). Fluo-4 acetoxymethyl (AM) and BCECF-AM (2,0 70-
bis-[2-carboxyethyl]-5-[and-6]-carboxyfluorescein; AM ester derivative) were
obtained from Molecular Probes (Eugene, OR). M16-modified medium without
Phenol Red (EmbryoMax; M16M) was obtained from Millipore (Billerica,
MA). Human semen samples were obtained from the Department of Obstetrics
and Gynecology, University of North Carolina Memorial Hospital, Chapel Hill,
NC, and the use of samples in this study was approved by the Committee on the
Protection of the Rights of Human Subjects at the University of North Carolina,
School of Medicine Chapel Hill, NC. Informed consent was not required for
these samples. Monkey anti-EPPIN antibodies were obtained from a previous
study [1] and were affinity purified as described previously [2]. As indicated in
our previous study [1], these antibodies were obtained following protocols
approved by our local Institutional Animal Care and Use Committee and the
Animal Ethics Committee and the Committee for the Purpose of Control and
Supervision of Experiments on Animals (India). Affinity purified rabbit
antibodies to the C terminal of EPPIN (amino acids 103–123) were produced
by Bethyl Laboratories, Inc. (Montgomery, TX) to the peptide SMFVYG-
GAQGNNNNFQSKANC (anti-S21C antibody), in which alanine was
substituted for cysteine 110. The Student t-test was used as a test of
significance to test the null hypothesis that the means of the two populations are
equal. A P value of 0.05 was considered significant.
Preparation of Spermatozoa
Semen samples collected from fertile donors at the UNC North Carolina
Memorial Hospital infertility clinic were allowed to liquefy for 30 min and
subjected to standard semen analysis. Acceptable samples were either used
fresh or stored in liquid nitrogen. Samples for study were prepared as
previously described [2]. For some preparations, an isolate gradient (Irving
Scientific, Irving, CA) was used to prepare spermatozoa. All experiments in
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this study were carried out with ‘‘swim up’’ spermatozoa in M16M buffer.
Incubation of spermatozoa with various concentrations of SEMG1 (0–14.4
lM), immunoglobulin G (IgG; 0–0.15 mg/ml), Fab (0–0.1 mg/ml), or monkey
anti-EPPIN (0–1 mg/ml) was carried out in 96-well plates as described below or
in 12- 3 75-mm glass tubes at 378C. Each experiment reported was repeated
with spermatozoa from at least three different ejaculate samples.
Fluo-4 AM Loading
Fluo-4 AM was dissolved in dimethyl sulfoxide and dispersed in 10%
Pluronic F-127 in H2O to make a stock solution of 1 mM. Human spermatozoa
were loaded with 10 lM Fluo-4 AM for 30 min at 378C in a shaking water
bath, diluted with 5 ml of M16M, and centrifuged at 300 3 g for 5 min.
Spermatozoa were resuspended in M16M or medium required for experimental
conditions and incubated for an additional 10–15 min before use. Aliquots were
taken to determine percentage of motility and sperm concentration.
Analysis of Sperm Motility
The analysis of sperm motility was carried out as previously described with
either Zeiss Cell Observer time lapse and tracking software (AxioVs40 version
4.6.3.0) [2] or computer-assisted sperm analysis (CASA) ( Ceros version 12.3
software; Hamilton-Thorne) [8]. In the Zeiss Cell Observer system, either a
Plan-Neofluar 103/0.3 phase 1, a Plan-Apochromat 203/0.8 phase 2 (diameter
width, 0.55 mm), a Plan-Neofluar 403/0.75 phase 2, or a Plan-Apochromat
633/1.4 phase 2 objective on a Zeiss Axiophot microscope was used. At least
four random fields were selected, and sperm motility was recorded with an
Axiocam HSc high-speed camera. Recordings were made for 1 sec at frame
rates varying between 53 and 111 frames/sec with a pixel window of either 660
3 492 or 328 3 248 pixels, depending upon the experiment. Sperm recordings
were analyzed with Zeiss Cell Observer time lapse and tracking software
(AxioVs40 version 4.6.3.0). To track spermatozoa, we placed the centroid [10]
over the posterior aspect of the head, which was tracked by the computer as the
spermatozoon moved along its path (Fig. 1, A and B). Parameters measured
were curvilinear velocity (VCL), amplitude of lateral head displacement (ALH)
and beat/cross frequency (BCF) [10]. Measurements were conducted at 248C.
The parameters of the Hamilton-Thorne Ceros 12.3 software system have been
described in our previous publication (Table 1 in reference 8).
Measurement of Intracellular Free Calcium
Fluo-4 AM-loaded spermatozoa were pipetted into 96-well black-walled
plates (Perkin Elmer, Waltham, MA) at 1.1 3 105–0.9 3 105 spermatozoa/well
in 50 ll of M16M at 378C, and read in a BioTek (Winookski, VT) Synergy2
Multiplatform automated plate reader (with heater and shaker). Wells were
excited using a 485/20 filter, and emission was read with a 528/20 filter, and
data were acquired using a kinetic modification of the Alexafluor 488 protocol
in the Gen5 software program (BioTek). Calibration of Fluo-4 in the plates
showed that metal-free Fluo-4 had 1/183 the fluorescence of the calcium-
saturated complex. After treatment of spermatozoa in each well with control or
test reagents was completed (10–15 min), the Fluo-4 in the spermatozoa in each
well was calibrated by adding ionomycin (2.5 lM), followed 15 min later by
the addition of Mn2þ (2 mM MnCl2) to bring the fluorescence (F) to 30% of
that of the saturated dye. Fifteen min later, lysis of the spermatozoa with 1%
Triton X-100 gave the background signal. Using these values for each well, the
Fmax and Fmin were calculated according to the method of Kao et al. [11].
Fluorescence measurements were converted to calcium concentration according
to the equation [Ca2þ]¼Kd ([F Fmin]/[Fmax F]) [11]. The Kd (dissociation
constant) for Fluo-4¼ 345 nM [12]. Readings for each well were normalized,
averaged, and expressed as percentages. Data from three ejaculate samples are
reported.
Dye leakage [12] from Fluo-4-loaded spermatozoa was measured by
removing spermatozoa every 15 min (from t ¼ 5 to t ¼ 65 min) from the
incubation medium by centrifugation and measurement of Fluo-4 fluorescence
in the supernatant. There was minimal leakage at 15 min and ;5% leakage
after 1 h incubation.
FIG. 1. Inhibition of human sperm motility by semenogelin-coated beads. A and B) Computer tracks of control spermatozoa at the beginning of their
tracks (A) and the same spermatozoa (B) in frame 51 of 103 frames taken in 1 sec.; 203 objective; 103 frames/sec; pixel window, 328 3 248. Note that the
centroid is in the posterior head region. Bar¼ 10 lm. C) Video frame of computer tracks of control spermatozoa (Supplemental Movie S1) treated with
EPPIN-coated beads. The sperm bind very few beads, which appear as black dots in the frame, and their motility is not affected; 103 objective; 58 frames/
sec; pixel window, 660 3 492. Bar¼50lm. D) Video frame of spermatozoon (Supplemental Movie S2) treated with SEMG1-coated beads; 633 objective;
57 frames/sec; pixel window, 660 3 492. Beads are bound to the sperm in the neck middle piece region and the distal end of the flagellum (arrows). Bar¼
2 lm. E) A computer track of a nonprogressive spermatozoon treated with SEMG1-coated beads, only lateral head movement is detected by the computer.
The other spermatozoon is not motile. Beads can be seen bound to the principal piece of the tail (arrow) and in the neck posterior head region; 403
objective; 53 frames/sec; pixel window, 660 3 492. Bar¼ 10 lm. Inset: high magnification of a single spermatozoon (633 objective) with bound beads











The AM ester derivative of the pH-sensitive dye BCECF (5 lM; Molecular
Probes) was used to detect changes in the pH in spermatozoa treated with
SEMG1. Spermatozoa were loaded with BCECF-AM for 30 min in bovine
serum albumin-free medium, centrifuged to remove extracellular dye, and
resuspended in M16M. Changes to 1.1 3 105–0.9 3 105 spermatozoa/well in 50
ll of M16M at 378C after treatment with 3.2 lM SEMG1 were monitored in a
BioTek (Winookski, VT) Synergy2 Multiplatform automated plate reader (with
heater and shaker); wells were excited using a 485/20 filter and emission read
with a 528/20 filter. Fluorescence was read immediately and recorded every 10
sec; readings for each time point were normalized, averaged, and expressed as
percentages of decrease in relative fluorescent units. Data from three ejaculate
samples are reported.
Preparation of Semenogelin-Coated Beads
Streptavidin-coated 0.49-lm microspheres (Bangs Laboratories, Fishers,
IN) were bound to biotinylated recombinant SEMG1 at 110% of saturation,
blocked, and washed according to the manufacturer’s directions. Beads were
resuspended at a concentration of 5 mg of beads/ml. Biotinylated recombinant
EPPIN was bound to streptavidin-coated 0.49-lm microspheres to serve as
control beads because EPPIN will bind to the sperm surface [4] but has no
affect on motility. For treatment of spermatozoa, we incubated ;104
spermatozoa with 2 ll of beads in 110 ll of M16M buffer at 378 C for 1–2
h. After a loss of motility was observed, we added thimerosal to a final
concentration of 50 lM.
Preparation of Fab Fragments
IgG was purified from preimmune serum on protein A agarose beads
(Pierce, Rockford IL). Affinity purified S21C and preimmune IgG were
digested on papain-agarose, using a Fab preparation kit (Pierce). Digestion was
confirmed by SDS-PAGE, and purified Fab fragments were concentrated and
dialyzed against PBS (pH 7.4).
RESULTS
SEMG1 Treatment of Spermatozoa
SEMG1 binds EPPIN on the human sperm surface and
inhibits progressive motility [2, 4, 8] in a binding site thought
to be similar to that of anti-EPPIN antibody S21C [4] because
in vitro assays demonstrate that SEMG1 will compete with the
S21C antibody for binding to EPPIN [4, 13]. To study
spermatozoa showing decreased progressive motility after
treatment with recombinant SEMG1, we tracked individual
spermatozoa with 0.49-lm streptavidin-biotinylated recombi-
nant SEMG1 beads attached. This ensured that the SEMG1
was acting on the sperm surface.
Sperm movement can be visualized by computer tracks,
which are shown in Figure 1, A, B, C, and E. Control
spermatozoa are shown in Figure 1, A, B, and C. Figure 1, A
and B, demonstrates the computer tracks of two control
spermatozoa in M16-modified medium (M16M), pH 7.4; in
Figure 1A, the spermatozoa are at the beginning of their tracks,
while in Figure 1B, the same spermatozoa are in frame 51 of 103
frames taken in 1 sec. The spermatozoon on track 1 has a VCL
of 86 lm/sec (ALH ¼ 3.8 lm; BCF ¼ 23 Hz), and the
spermatozoon on track 2 has a VCL of 125 lm/sec (ALH¼ 7.8
lm; BCF ¼ 16 Hz). Control spermatozoa are also shown in
Figure 1C at lower magnification to demonstrate that treatment
with EPPIN-coated control beads does not affect their motility.
Figure 1C is a video frame from Supplemental Movie S1
(Supplemental Data are available online at www.biolreprod.org).
Spermatozoa treated with SEMG1-coated beads are shown
in Figure 1, D and E. Figure 1D is a video frame from
Supplemental Movie S2 and demonstrates the nonprogressive
motility of a spermatozoon with bound SEMG1-coated beads
(Supplemental Movie S2, arrows). There is no track for this
spermatozoon because the centroid placed over the posterior
aspect of the head does not move. A nonprogressive
spermatozoon treated with SEMG1-coated beads with a
computer track is shown in Figure 1E. Only slight lateral head
movement was detected by the computer. The other sperma-
tozoon in Figure 1E was not motile, and beads can be seen
bound to the principal piece of the tail (Fig. 1E inset, arrow). In
the inset at higher magnification a spermatozoon with beads on
the neck-posterior head region and principal piece (Fig. 1E,
arrow) can be seen. CASA measurements confirmed that the
percentages of motile and progressive sperm decreased with
SEMG1-bead treatment compared to EPPIN-bead treatment
(Fig. 2; data 6 SEM are from three ejaculates). We previously
established, using CASA, the fact that spermatozoa treated
with recombinant SEMG1 begin to lose their progressive
motility after 15–30 min [8].
The inositol trisphosphate (IP3) receptor agonist thimerosal
has been shown to induce hyperactivation and an increase in
high-amplitude flagella bending in mice [14, 15]. To determine
if thimerosal could restimulate motility in SEMG1 bead-treated
spermatozoa, we treated spermatozoa with 50 lM thimerosal.
As shown in Figure 2, CASA measurements demonstrate that
the percentage of motile sperm and the percentage of
progressive sperm recover after thimerosal treatment, indicat-
ing that flagellar activity can be reactivated in SEMG1-treated
spermatozoa. The recovery of VCL and ALH parameters was
not significant (Fig. 2). Thimerosal treatment had no significant
effect on the percentage of motile sperm when spermatozoa
were treated with control EPPIN-coated beads (data not
shown).
Calcium Changes in Spermatozoa Treated with SEMG1
To study changes in calcium concentration in human
spermatozoa, we first established the fact that there was no
difference between the motility of sperm loaded with the
calcium indicator Fluo-4 in M16-modified medium (M16M)
and unloaded sperm in wells of a single 96-well black-walled
plate in the automated plate reader. The VCL of human
TABLE 1. Recovery of motility after NH4Cl treatment of SEMG1-treated spermatozoa.*
Treatment Motile (%) Progressive (%) VCL (lm/sec) ALH (lm)
Control 79 63 65 6 7 101 6 11 4.3 6 0.1
SEMG1 54 6 6a 41 6 10 78 6 14 3.1 6 0.1b
SEMG1 þ NH4Cl 80 6 6
c,d 60 6 16d 107 6 7d 4.6 6 0.7c,d
* Data are from CASA measurements of three ejaculates 6 SD.
a P¼ 0.03 versus control.
b P¼ 0.007 versus control.
c P¼ 0.05 versus SEMG1.
d P¼ not significant versus control.
 SEMG1¼ 0.1 mg/ml; 2 3 106 sperm/ml; 50 pg/sperm; 10 mM NH4Cl.









spermatozoa loaded with the calcium indicator Fluo-4 in
M16M (156 6 65 lm/sec) did not differ from that of unloaded
spermatozoa (156 6 35.5 lm/sec; n ¼ 6 replicate wells; .25
sperm tracks) when incubated in a 5% CO2 incubator at 378C.
After 1 h, the motility characteristics of Fluo-4-loaded
spermatozoa in a 5% CO2 incubator at 378C (123 6 8 lm/
sec) were not significantly different (P¼ 0.59 for VCL; n¼ 6
replicate wells; .25 sperm tracks) from those of Fluo-4-loaded
spermatozoa incubated for 1 h in M16M in the multiwell plate
at 378C (116 6 45 lm/sec).
As described in Materials and Methods, spermatozoa in
each well were treated with control or test reagents, and the
Fluo-4 in the spermatozoa in each well was calibrated. A
representative trace of the fluorescence signal is shown in
Figure 3A. After 15 min of treatment, ionomycin was added
(2.5 lM) (Fig. 3A, arrow), causing an immediate spike in the
fluorescence signal. Fifteen minutes later, MnCl2 (2 mM) (Fig.
3A, arrowhead) was added, which caused an immediate drop in
the fluorescence signal. Fifteen minutes later, spermatozoa
were lysed with 1% Triton X-100 to be sure that background
readings had been obtained.
Spermatozoa treated with SEMG1 (or SEMG1-coated
beads, data not shown) showed a significant decrease in Fluo4
signal compared to spermatozoa treated with buffer or control
beads. Figure 3B shows a dose-response curve demonstrating





]i) by approximately 30%. As previously
reported [8], spermatozoa treated with SEMG1 lose their
motility in a time- and concentration-dependent manner. As
shown in Figure 3B, as the [Ca2
þ
]i decreases, sperm motility,
measured by CASA, also decreases. Spermatozoa treated with
SEMG1-coated beads showed a similar decrease in intracellu-
lar [Ca2
þ
]i compared to spermatozoa treated with control beads
(22.4%, with a pool of four donors, n ¼ 4 experiments, P ¼
0.02, at 30 min). Calcium levels after thimerosal treatment
could not be measured because thimerosal interferes with the
calibration steps (maximum and minimum cannot be accurately
measured).
Calcium levels are affected by intracellular pH [16, 17];
therefore, we asked whether treatment of spermatozoa with
SEMG1 changed the intracellular pH. Spermatozoa were
loaded with BCECF and treated with 3.2 lM SEMG1, and
the fluorescence was monitored in 96-well plates. Within 1
min, there was a 15% decrease in relative fluorescent units;
with a plateau after 5–6 min (Fig. 3C). To determine if motility
could be reversed by intracellular alkalization, 30 min after
SEMG1 treatment, we treated spermatozoa with 10 mM
NH4Cl. CASA measurements demonstrated that after treatment
with NH4Cl, the spermatozoa recover to pre-SEMG1 treatment
levels (Table 1). Similar to thimerosal, calcium levels after
NH4Cl treatment could not be measured because NH4Cl
interferes with the calibration steps (maximum and minimum
cannot be accurately measured).
Calcium Changes in Spermatozoa Treated with anti-EPPIN
Antibodies
Previously [1], the contraceptive C-terminal epitope of
EPPIN was ident i f ied as amino acids 101–125
(TCSMFVYGGCQGNNNNFQSKANCLN). Affinity purified
rabbit antibodies (anti-S21C antibodies) to the EPPIN S21C
epitope (SMFVYGGAQGNNNNFQSKANC) had effects sim-
ilar to those of recombinant SEMG1, namely, the dose-
dependent inhibition of the progressive motility of spermatozoa
[4]. To determine if anti-EPPIN treatment would result in loss
of [Ca2þ]i, we treated spermatozoa loaded with the calcium
indicator Fluo-4 in M16-modified medium (M16M) in wells of
a single 96-well black-walled plate in the automated plate
reader with 150 lg/ml of anti-S21C antibody. Treatment of
spermatozoa with affinity purified S21C antibodies (IgG)
resulted in decreased levels of intracellular [Ca2
þ
]i, which
differed significantly from those seen in control rabbit IgG-
treated samples or M16M buffer controls. Data from five
ejaculate samples demonstrated a 52% decrease in [Ca2
þ
]i after
treatment with anti-S21C (Fig. 3D).
The two antigen binding sites of anti-S21C IgG molecules
could influence the lateral mobility of the eppin protein
complex in the plane of the membrane and thereby disrupt
calcium uptake into the cell. To address this possibility, Fab
fragments with only a single antigen binding site were tested
for their effect on the levels of intracellular [Ca2
þ
]i. Similar to
the treatment with anti-S21C IgG, treatment of spermatozoa
with anti-S21C Fab fragments (100 lg/ml) resulted in a 66%
decrease in the level of intracellular calcium (Fig. 3D; data
from eight ejaculates). Moreover, treatment with S21C Fab
resulted in a 58% loss of VCL after 10 min (115 lm/sec vs. 49
lm/sec, P ¼ 5.7 3 108; n ¼ 3 ejaculates) and a reduction of
ALH from 3.7 6 1 lm to 1.9 6 0.9 lm (P¼ 3.7 3 106; n¼ 3
ejaculates). After 20 min of treatment with S21C Fab, there
was a complete loss of progressive motility such that
spermatozoa were twitching or vibrating in place, whereas
spermatozoa treated with control Fab were unaffected.
To confirm that antibodies to the S21C binding site had
effects similar to those of contraceptive antibodies from
infertile male monkeys, Fluo-4-loaded spermatozoa were
incubated in affinity purified anti-EPPIN antibodies obtained
from infertile male monkeys [1]. Antibodies from three male
monkeys, d523/602, d523/619, and d523/625, depressed the
[Ca2þ]i normally seen in control samples by 33%, 33%, and
38%, respectively (Fig. 3D; data from three ejaculates). Control
spermatozoa treated with M16M or adjuvant control IgG (data
not shown) did not show decreased levels of [Ca2
þ
]i over the
same incubation time period.
FIG. 2. Thimerosal treatment. Recovery of motility in SEMG1 bead-
treated spermatozoa after treatment with 50 lM thimerosal. Data are from
three ejaculates; normalized data are presented as the mean 6 SEM.
Motile, percentage of motile; Progressive, percentage of progressive
motility; VCL, curvilinear velocity; ALH, amplitude of lateral head












During ejaculation, SEMG1 binds to EPPIN [3, 5],
inhibiting the progressive motility of ejaculate spermatozoa.
The present study has demonstrated that when SEMG1binds to
human spermatozoa, intracellular calcium levels decrease (Fig.
3B). During semen liquefaction, activated PSA in the ejaculate
hydrolyzes SEMG1 [7], removing it from the sperm surface
and resulting in the activation of motility. As motility begins,
intracellular calcium levels in the noncapacitated spermatozoa
are at basal levels, usually ,100 nM (range 40–100 nM) [18,
19], and increase over time with incubation under capacitating
conditions [20]. Significant increases in intracellular calcium
are then required for hyperactivation and subsequent fertiliza-
tion [21]. The normal motility of ejaculate human spermatozoa
can be reversed by SEMG1 and again reactivated by PSA
treatment [8]. We conclude from the results reported here that
under normal physiological conditions, when seminal plasma is
added to spermatozoa during ejaculation, the observed
inhibition of sperm motility before liquefaction is most likely
caused by the lack of intracellular calcium brought about by the
binding of SEMG1 to EPPIN.
Thimerosal, an inositol triphosphate (IP3) receptor agonist
that induces hyperactivation and an increase in high-amplitude
flagella bending [14, 15], has been shown to release calcium
from internal stores [22, 15]. Our finding that thimerosal will
stimulate motility in spermatozoa treated with SEMG1 (Fig. 2)
indicates that the binding of SEMG1 to the sperm plasma
membrane most likely did not deplete internal calcium stores.
FIG. 3. A) Time plot of Fluo-4 fluorescence intensity. A representative trace is shown of the fluorescence signal from a single well of a 96-well plate
containing Fluo-4-loaded spermatozoa in M16M. After 15 min, ionomycin was added (2.5 lM [arrow]), causing an immediate spike in the fluorescence
signal. Fifteen minutes later, MnCl2 (2 mM [arrowhead]) was added, which caused an immediate drop in the fluorescence signal. B) Loss of Intracellular
[Ca2þ] in human spermatozoa treated with SEMG1. Fluo-4-loaded spermatozoa were washed by centrifugation and resuspended in M16M and pipetted
into a 96-well plate containing either control M16M medium or SEMG1. A dose-response curve of spermatozoa treated with increasing concentrations of
SEMG1 (1.8, 3.6, 7.2, 14.4 lM). Data are from three ejaculates after 15 min of treatment; normalized data are presented as the means 6 SD. Motility
measurements were made by CASA. C) Fluorescence of the pH indicator BCECF in 1.1 3 105–0.9 3 105 spermatozoa/well in 50 ll of M16M at 378C after
treatment with 3.2 lM SEMG1. Spermatozoa were monitored in a BioTek Synergy2 multiplatform automated plate reader. Data are from three ejaculates;
normalized data are presented as the means 6 SD. D) Loss of [Ca2þ]i in human spermatozoa treated with affinity purified anti-EPPIN antibodies. Fluo-4-
loaded spermatozoa were washed by centrifugation and resuspended in M16M and pipetted into a 96-well plate containing either control M16M medium
or antibodies. S21C Fab, affinity purified anti-EPPIN epitope Fab antibodies, 100 lg/ml, eight ejaculates; S21C IgG, affinity purified anti-EPPIN epitope
IgG antibodies, 150 lg/ml, five ejaculates; IgG 523/602; 523/619; 523/625, affinity purified monkey anti-EPPIN IgG antibodies from three different
monkeys (day/monkey number), 1mg/ml, three ejaculates. Normalized data are presented as the means 6 SD. All samples are significantly different from
controls (P , 0.05).









The low-bend amplitude of flagella (ALH), characteristic of
SEMG1 treatment (,3.6 6 0.8 lm), is indicative of low
intracellular calcium and has been shown to be increased after
thimerosal treatment [15]. Although we favor the conclusion
that SEMG1 treatment blocked calcium uptake, we cannot rule
out the possibility that calcium loss from the spermatozoon was







exchanger [23, 24]. Further experiments will be
necessary to test these possibilities.
The effects of pH on sperm motility are well documented
[25, 26], and increased intracellular calcium levels are known
to depend upon an internal alkaline pH [22, 27, 28]. In order to
determine whether SEMG1 binding changed the internal pH of
spermatozoa, we tested spermatozoa loaded with BCECF and
monitored fluorescence changes (Fig. 3C). The rapid decrease
in relative fluorescent units most likely indicates that there was
a drop in intracellular pH and that SEMG1 binding may have
changed the polarity of the plasma membrane. The low-bend
amplitude of flagella (ALH), characteristic of SEMG1
treatment, is characteristic of low intracellular pH (pH 6.6)
[22] (ALH¼ 1.6 6 0.6 lm at pH 6.7 for human spermatozoa
[O’Rand and Widgren unpublished observations]). To test
whether the loss of motility in SEMG1-treated spermatozoa
could be reversed by intracellular alkalization, we treated
spermatozoa with NH4Cl to raise the pH. NH4Cl has been
shown to increase intracellular pH and calcium levels [22]. Our
results indicate that motility parameters characteristic of
activated spermatozoa were restored to SEMG1-treated
spermatozoa (Table 1). This result may be interpreted to mean
that the loss of calcium by SEMG1 treatment is from an
upstream effect on the intracellular pH rather than a direct
blocking effect of a calcium channel.
Several different plasma membrane calcium channels exist
in human spermatozoa, including transient receptor potential
channels (TRPM8) [29] and the CATSPER calcium channel
that is activated by intracellular alkalinization [28, 30].
Whether the EPPIN protein complex on the surface of
spermatozoa, in the presence of SEMG1, interacts with the
CATSPER channels is unknown; however, it has been reported
that sperm from Catsper/ null mice show motility as if they
have low intracellular calcium levels [15], and the motility can
be restored by release of calcium stores [15]. Although the
mechanism through which SEMG1 and anti-EPPIN antibodies
exert their effectiveness might be a disruption of CATSPER,
alternatively, our BCECF and NH4Cl data indicate that it might
be a disruption of intracellular pH. The voltage-gated HVCN1
proton channel [17] is present in human spermatozoa [28], and
the presence of anti-EPPIN antibodies or SEMG1 bound to the
EPPIN protein complex on the sperm surface could inhibit or
reverse intracellular alkalinization, leading to an inhibition of
calcium uptake and a loss of progressive motility. The motility
characteristics of spermatozoa at low pH are similar to those
observed in the presence of anti-EPPIN or SEMG1, suggesting
that an inhibition of calcium uptake could be occurring through
a change in activity of a proton channel.
Treatment of human spermatozoa with anti-EPPIN antibod-
ies (anti-S21C) specific to the C terminal of EPPIN (Fig. 3D) or
from infertile male monkeys (Fig. 3D) produced a significant
loss of calcium that is accompanied by the previously reported
significant decrease in progressive motility [4]. Interestingly,
the dual binding sites of IgG, which might induce lateral
association of plasma membrane surface molecules, were not
responsible for the loss of calcium. The significant loss of
calcium by the S21C Fab antibody (Fig. 3D) indicates that
binding directly to the EPPIN epitope perturbs the surface
enough to affect calcium levels, velocity, and flagella
amplitude. Decreases in flagella beat amplitude and progres-
sive motility resulting from decreased intracellular calcium
have been reported previously [16] when measured using
ethylene glycol tetraacetic acid (EGTA) to decrease external
calcium concentrations.
The results of this study demonstrate that the male
contraceptive target EPPIN controls sperm motility in the
ejaculate by binding SEMG1, resulting in a loss of intracellular
calcium. Anti-EPPIN antibodies can substitute for SEMG1,
and, therefore, small-molecular weight compounds that mimic
anti-EPPIN binding should be able to substitute for SEMG1,
providing the basis for a nonantibody, nonhormonal male
contraceptive.
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